Cinacalcet - An allosteric enhancer at the Ca2+-receptor;Cinacalcet - Ein allosterischer verstärker am Ca2+-rezeptor

Deutsche Medizinische Wochenschrift

Volumn 133, Issue 33, 2008, Pages 1681-1683

  Kebig, A ^a   Mohr, Klaus ^a,b  

^a UNIVERSITY OF BONN   (Germany)

^b NONE   (Germany)

Author keywords

Ca2+ receptor; Cinacalcet; Secondary hyperparathyroidism

Indexed keywords

CINACALCET; CALCIUM; CALCIUM SENSING RECEPTOR; NAPHTHALENE DERIVATIVE; PARATHYROID HORMONE;

ALLOSTERISM; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; PARATHYROIDECTOMY; REVIEW; BLOOD; CHEMISTRY; CHRONIC KIDNEY FAILURE; DRUG EFFECT; DRUG MONITORING; DRUG POTENTIATION; METABOLISM; METHODOLOGY; PARATHYROID TUMOR; RENAL REPLACEMENT THERAPY; SECONDARY HYPERPARATHYROIDISM;

CALCIUM; DRUG MONITORING; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; NAPHTHALENES; PARATHYROID HORMONE; PARATHYROID NEOPLASMS; RECEPTORS, CALCIUM-SENSING; RENAL DIALYSIS;

EID: 49649085324     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0028-1082785     Document Type: Review

References (16)

1. Arzneimittelbrief: Behandlung des sekundären Hyperparathyreoidismus bei Hämodialysepatienten mit dem Kalzimimetikum Cinacalcet. AMB 2005; 39: 05
2. Arzneimittelbrief: Neue Arzneimittel 2004. AMB 2006; 40: 02
3. Block AG, Martin KJ, de Francisco ALM et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516-1525
4. Chertow GM, Pupim LB, Block GA et al.. Evaluation of cinacalcet therapy to lower cardiovascular events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol 2007; 2 (5): 898-905
5. Cunningham J, Danese M, Oslon K et al. Effects of the calcimimetic cinacalcet HCL on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68: 1793-1800
6. Drugdex®, DrugPoinr® Summary Cinacalcet Hydrochloride Stand Dezember 2007
7. Fachinformation Cinacalcet Stand Juli 2006
8. Gal-Moscovici A, Popovtzer MM. New worldwide trends in presentation of renal osteodystrophy and its relationship to parathyroid hormone levels. Clin Nephrol 2005; 63: 284-289
9. Lien YH, Silva AL, Whittman D. Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2005; 20: 1232-1237
10. Lindberg JS, Culleton B, Wong G et al. Cinacalcet HCL, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis. J Am Soc Nephrol 2005; 16: 800-807
11. Moe SM, Chertow GM, Coburn JW et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005; 67: 760-771
12. Moe SM, Cunningham J, Bommer J et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant 2005; 20: 2186-2193
13. NICE technology appraisal guidance 117: Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy January 2007
14. Silverberg SJ, Rubin MR, Faiman C et al. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab 2007; 92: 3803-3808
15. Steddon SJ, Cunningham J. Calcimimetics and calcilytics - fooling the calcium receptor. Lancet 2005; 365: 2237-39
16. Sterrett JR, Strom J, Stummvoll HK et al. Cinacalcet HCl (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 2007; 68: 10-17